Felipe K. Hurtado, Emily Schapiro, Elizabeth Lusk, Isabelle Laure Ray-Coquard, Lydia Gaba, Kosei Hasegawa, Alexander Philipovskiy, Izna Ali, Youngjun Yoo, Hiroyuki Inoue, Tsvetomir Mitov, Guillaume Bergthold, Yvonne Lau. "Exposure–response (E–R) analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed antibod-drug conjugate (ADC), to inform dose selection for phase (Ph) 3 development in platinum-resistant ovarian cancer (PROC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.5570